XTNT vs. EXEL

Last updated Apr 1, 2026

Compare and contrast key facts about Xtant Medical Holdings, Inc. (XTNT) and Exelixis, Inc. (EXEL).

Performance

XTNT vs. EXEL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Xtant Medical Holdings, Inc. (XTNT) and Exelixis, Inc. (EXEL). The values are adjusted to include any dividend payments, if applicable.

XTNT vs. EXEL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
XTNT Xtant Medical Holdings, Inc.	-28.83%	76.98%	-60.80%	71.21%	17.86%	-53.18%	-25.24%	-0.62%	-76.56%	4.09%
EXEL Exelixis, Inc.	-2.14%	31.62%	38.81%	49.56%	-12.25%	-8.92%	13.90%	-10.42%	-35.30%	103.89%

Fundamentals

EPS XTNT : $0.09 EXEL : $2.76
PE Ratio XTNT : 6.16 EXEL : 15.52
PS Ratio XTNT : 0.41 EXEL : 5.24
Total Revenue (TTM) XTNT : $133.93M EXEL : $2.32B
Gross Profit (TTM) XTNT : $84.27M EXEL : $2.24B
EBITDA (TTM) XTNT : $22.15M EXEL : $934.65M

Returns By Period

In the year-to-date period, XTNT achieves a -28.83% return, which is significantly lower than EXEL's -2.14% return. Over the past 10 years, XTNT has underperformed EXEL with an annualized return of -33.05%, while EXEL has yielded a comparatively higher 26.62% annualized return.

XTNT

• 1D: 2.76%
• 1M: -2.16%
• YTD: -28.83%
• 6M: -14.01%
• 1Y: 18.72%
• 3Y*: -4.34%
• 5Y*: -24.73%
• 10Y*: -33.05%

EXEL

• 1D: 2.24%
• 1M: -2.66%
• YTD: -2.14%
• 6M: 3.85%
• 1Y: 16.17%
• 3Y*: 30.25%
• 5Y*: 13.15%
• 10Y*: 26.62%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

XTNT vs. EXEL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XTNT

XTNT Risk / Return Rank: 51
XTNT Sharpe Ratio Rank: 52
XTNT Sortino Ratio Rank: 54
XTNT Omega Ratio Rank: 51
XTNT Calmar Ratio Rank: 50
XTNT Martin Ratio Rank: 49

EXEL

EXEL Risk / Return Rank: 56
EXEL Sharpe Ratio Rank: 56
EXEL Sortino Ratio Rank: 52
EXEL Omega Ratio Rank: 54
EXEL Calmar Ratio Rank: 58
EXEL Martin Ratio Rank: 58

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XTNT vs. EXEL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Xtant Medical Holdings, Inc. (XTNT) and Exelixis, Inc. (EXEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	XTNT	EXEL	Difference
Sharpe ratio Return per unit of total volatility	0.28	0.37	-0.09
Sortino ratio Return per unit of downside risk	0.94	0.83	+0.11
Omega ratio Gain probability vs. loss probability	1.11	1.12	-0.01
Calmar ratio Return relative to maximum drawdown	0.34	0.67	-0.32
Martin ratio Return relative to average drawdown	0.66	1.55	-0.90
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

XTNT vs. EXEL - Sharpe Ratio Comparison

The current XTNT Sharpe Ratio is 0.28, which is comparable to the EXEL Sharpe Ratio of 0.37. The chart below compares the historical Sharpe Ratios of XTNT and EXEL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	XTNT	EXEL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.28	0.37	-0.09
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.33	0.36	-0.69
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.29	0.60	-0.89
Sharpe Ratio (All Time) Calculated using the full available price history	-0.30	0.07	-0.37

Correlation

The correlation between XTNT and EXEL is 0.04, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

XTNT vs. EXEL - Dividend Comparison

Neither XTNT nor EXEL has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

XTNT vs. EXEL - Drawdown Comparison

The maximum XTNT drawdown since its inception was -99.17%, roughly equal to the maximum EXEL drawdown of -97.38%. Use the drawdown chart below to compare losses from any high point for XTNT and EXEL.

Drawdown Indicators

	XTNT	EXEL	Difference
Max Drawdown Largest peak-to-trough decline	-99.17%	-97.38%	-1.79%
Max Drawdown (1Y) Largest decline over 1 year	-40.98%	-25.34%	-15.64%
Max Drawdown (5Y) Largest decline over 5 years	-85.75%	-41.47%	-44.28%
Max Drawdown (10Y) Largest decline over 10 years	-98.86%	-57.20%	-41.66%
Current Drawdown Current decline from peak	-98.68%	-12.91%	-85.77%
Average Drawdown Average peak-to-trough decline	-88.61%	-71.55%	-17.06%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.33%	10.85%	+10.48%

Volatility

XTNT vs. EXEL - Volatility Comparison

Xtant Medical Holdings, Inc. (XTNT) has a higher volatility of 14.96% compared to Exelixis, Inc. (EXEL) at 6.86%. This indicates that XTNT's price experiences larger fluctuations and is considered to be riskier than EXEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XTNT	EXEL	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.96%	6.86%	+8.10%
Volatility (6M) Calculated over the trailing 6-month period	42.57%	26.58%	+15.99%
Volatility (1Y) Calculated over the trailing 1-year period	67.71%	43.76%	+23.95%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	74.19%	36.84%	+37.35%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	113.64%	44.88%	+68.76%

Financials

XTNT vs. EXEL - Profitability Comparison

The chart below illustrates the profitability comparison between Xtant Medical Holdings, Inc. and Exelixis, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

XTNT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Xtant Medical Holdings, Inc. reported a gross profit of 17.75M and revenue of 32.36M. Therefore, the gross margin over that period was 54.9%.

EXEL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported a gross profit of 572.18M and revenue of 598.66M. Therefore, the gross margin over that period was 95.6%.

XTNT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Xtant Medical Holdings, Inc. reported an operating income of -944.00K and revenue of 32.36M, resulting in an operating margin of -2.9%.

EXEL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported an operating income of 235.22M and revenue of 598.66M, resulting in an operating margin of 39.3%.

XTNT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Xtant Medical Holdings, Inc. reported a net income of 4.06M and revenue of 32.36M, resulting in a net margin of 12.6%.

EXEL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported a net income of 244.53M and revenue of 598.66M, resulting in a net margin of 40.9%.